|
1
|
Katiyar SK and Elmets CA: Green tea
polyphenolic antioxidants and skin photoprotection (Review). Int J
Oncol. 18:1307–1313. 2001.PubMed/NCBI
|
|
2
|
Singh BN, Shankar S and Srivastava RK:
Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms,
perspectives and clinical applications. Biochem Pharmacol.
82:1807–1821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mukhtar H and Ahmad N: Green tea in
chemoprevention of cancer. Toxicol Sci. 52(2 Suppl): S111–S117.
1999. View Article : Google Scholar
|
|
4
|
Hsu YC and Liou YM: The anti-cancer
effects of (-)-epigallocatechin-3-gallate on the signaling pathways
associated with membrane receptors in MCF-7 cells. J Cell Physiol.
226:2721–2730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shankar S, Ganapathy S, Hingorani SR and
Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and
metastasis of pancreatic cancer. Front Biosci. 13:440–452. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sukhthankar M, Alberti S and Baek SJ:
(-)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and
post-translationally suppresses the cell proliferative protein
TROP2 in human colorectal cancer cells. Anticancer Res.
30:2497–2503. 2010.PubMed/NCBI
|
|
7
|
Onoda C, Kuribayashi K, Nirasawa S, Tsuji
N, Tanaka M, Kobayashi D and Watanabe N:
(-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer
cell lines by down-regulating survivin expression. Int J Oncol.
38:1403–1408. 2011.PubMed/NCBI
|
|
8
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar
|
|
9
|
Urban N and Drescher C: Potential and
limitations in early diagnosis of ovarian cancer. Adv Exp Med Biol.
622:3–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizutani K, Ito H, Iwamoto I, et al:
Essential roles of ERK-mediated phosphorylation of vinexin in cell
spreading, migration and anchorage-independent growth. Oncogene.
26:7122–7131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ray RM, Vaidya RJ and Johnson LR: MEK/ERK
regulates adherens junctions and migration through Rac1. Cell Motil
Cytoskeleton. 64:143–156. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang YH, Yang IJ and Shin HM: Herbal
formula HMC05 prevents human aortic smooth muscle cell migration
and proliferation by inhibiting the ERK1/2 MAPK signaling cascade.
J Nat Med. 66:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gayer CP, Craig DH, Flanigan TL, Reed TD,
Cress DE and Basson MD: ERK regulates strain-induced migration and
proliferation from different subcellular locations. J Cell Biochem.
109:711–725. 2010.PubMed/NCBI
|
|
15
|
Tangkijvanich P, Santiskulvong C, Melton
AC, Rozengurt E and Yee HF Jr: p38 MAP kinase mediates
platelet-derived growth factor-stimulated migration of hepatic
myofibroblasts. J Cell Physiol. 191:351–361. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li T, Feng Z, Jia S, Wang W, Du Z, Chen N
and Chen Z: Daintain/AIF-1 promotes breast cancer cell migration by
up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast
Cancer Res Treat. 131:891–898. 2012.PubMed/NCBI
|
|
17
|
Xue A, Xue M, Jackson C and Smith RC:
Suppression of urokinase plasminogen activator receptor inhibits
proliferation and migration of pancreatic adenocarcinoma cells via
regulation of ERK/p38 signaling. Int J Biochem Cell Biol.
41:1731–1738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Choi BD, Jeong SJ, Wang G, Park JJ, Lim
DS, Kim BH, Cho YI, Kim CS and Jeong MJ: Secretory leukocyte
protease inhibitor is associated with MMP-2 and MMP-9 to promote
migration and invasion in SNU638 gastric cancer cells. Int J Mol
Med. 28:527–534. 2011.PubMed/NCBI
|
|
19
|
Malemud CJ: Matrix metalloproteinases
(MMPs) in health and disease: an overview. Front Biosci.
11:1696–1701. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hilger RA, Scheulen ME and Strumberg D:
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie.
25:511–518. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geest CR and Coffer PJ: MAPK signaling
pathways in the regulation of hematopoiesis. J Leukoc Biol.
86:237–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brooks SA, Lomax-Browne HJ, Carter TM, et
al: Molecular interactions in cancer cell metastasis. Acta
Histochem. 112:3–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hwang ES and Park KK: Magnolol suppresses
metastasis via inhibition of invasion, migration, and matrix
metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma
cells. Biosci Biotechnol Biochem. 74:961–967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun LC, Luo J, Mackey LV, Fuselier JA and
Coy DH: A conjugate of camptothecin and a somatostatin analog
against prostate cancer cell invasion via a possible signaling
pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Cancer Lett. 246:157–166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmalfeldt B, Prechtel D, Härting K,
Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W
and Lengyel E: Increased expression of matrix metalloproteinases
(MMP)-2, MMP-9, and the urokinase-type plasminogen activator is
associated with progression from benign to advanced ovarian cancer.
Clin Cancer Res. 7:2396–2404. 2001.PubMed/NCBI
|
|
28
|
Deng YT and Lin JK: EGCG inhibits the
invasion of highly invasive CL1-5 lung cancer cells through
suppressing MMP-2 expression via JNK signaling and induces G2/M
arrest. J Agric Food Chem. 59:13318–13327. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sen T, Moulik S, Dutta A, Choudhury PR,
Banerji A, Das S, Roy M and Chatterjee A: Multifunctional effect of
epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A
(MMP-2) in human breast cancer cell line MCF-7. Life Sci.
84:194–204. 2009. View Article : Google Scholar : PubMed/NCBI
|
